Our latest news

Notification of Major Interest in Shares

31 December 2007

The Company has been notified that Mr Jim Mellon of Galloway Limited and Titec Limited now holds a total of 11,650,000 ordinary shares in Medical Solutions, representing 5.72% of the issued share capital.

For More Information

British Society for Clinical Cytology (BSCC) annual conference in Cardiff

01 November 2007

Medical Solutions exhibited at the British Society for Clinical Cytology (BSCC) annual conference in Cardiff where a number of clinical papers, from around the UK, were presented on the SurePath� liquid based cytology platform. These included a paper on the first UK trial to be completed using automated imaging and guided screening technology for cervical cancer screening. This trial was conducted by Cervical Screening Wales on 12,700 cervical smear samples over a six month period using the TriPath� FocalPoint� automated imaging platform with technical support provided by Medical Solutions. The trial demonstrated the utility of automated imaging as a quality assurance tool in the cervical cancer screening programme. The full results of this trial will be published in due course.

Additional SurePath� LBC contract secured

10 October 2007

Medical Solutions are pleased to confirm that Jersey NHS Trust have chosen the SurePath� liquid based cytology (LBC) system for their cervical screening programme and have signed a three year agreement worth approximately �150,000 in total. Training with the Trust will commence in November and roll out will be rapid.

Healthcare Division Activity

10 October 2007

The Diagnostic Pathology team were present at the 10th International Nottingham Breast Cancer Conference to promote their range of breast cancer diagnostic tests including HER2, Top2a and OncotypeDX, the prognostic profiling tool. This gave them the opportunity to network with breast surgeons and other healthcare professionals involved in breast cancer treatment and care from all over the UK and Europe. A UK based clinical utility assessment of OncotypeDX is being planned and a number of oncologists have expressed an interest in participating.

TIME magazine reviews latest advances in breast cancer diagnostics and treatment

08 October 2007

The 15 October edition of TIME magazine presents a review of the latest advances in breast cancer diagnostics and treatment, including Genomic Health's OncotypeDX breast cancer test, the molecular diagnostic test for which Medical Solutions is the exclusive distributor in the UK.

For More Information

Medical Solutions extends partnership with Oxford University and Achieves Extended ISO 9001:2000 Certification

08 October 2007

Medical Solutions is pleased to see the expansion of its DNA sequencing activities through an extended partnership with the University of Oxford. The DNA sequencing facility previously run by the Department of Pathology has been incorporated into Medical Solutions� Geneservice Oxford DNA sequencing laboratory, the second core laboratory to join forces with Geneservice since January. The company now has the largest commercial sequencing capability in both Cambridge and Oxford and looks forward to continued growth through similar partnering opportunities.

In addition to this, the sequencing laboratory at Oxford University has received the International Standards Organisation's (ISO) 9001:2000 certification for the provision of functional genomic products and contract research to academic and commercial research communities worldwide and to sequencing/contract research in satellite laboratories in the UK. This follows external validation by Lloyds Register of Quality Assurance (LRQA) a United Kingdom Accreditation Service (UKAS) accredited quality certification body. ISO 9001 is an internationally recognised standard that represents good management practices and aims to ensure that organisations consistently deliver the products or services that meet their clients� quality requirements. The achievement of ISO 9001:2000 approval reinforces Medical Solutions� continued commitment to identify and meet the needs and expectations of its customers and achieve, maintain and improve overall operational performance and capabilities

Dr Nick Leaves, Head of Operations, commented:
"This partnership and certification demonstrates Medical Solutions� constant determination and commitment to providing elite levels of both product and service quality. We are dedicated to being the premier supplier of genomic products and technical services to our customers."